Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus NYSTAFORM.
AMPHOTEC vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category C
Category C
Antifungal
Antifungal